このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

OncoCyte 将来の成長

Future 基準チェック /26

OncoCyteは、32.4%と64%でそれぞれ年率32.4%で利益と収益が成長すると予測される一方、EPSはgrowで51.9%年率。

主要情報

32.4%

収益成長率

51.9%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	64.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	17 May 2024

今後の成長に関する最新情報

Recent updates

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oct 28

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Aug 30

Here's What OncoCyte Corporation's (NASDAQ:OCX) Shareholder Ownership Structure Looks Like

Mar 18

業績と収益の成長予測

NasdaqCM:OCX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	11	-19	N/A	N/A	1
12/31/2025	5	-21	N/A	N/A	3
12/31/2024	2	-27	N/A	N/A	2
3/31/2024	1	-40	-19	-19	N/A
12/31/2023	2	-26	-24	-23	N/A
9/30/2023	1	-23	-28	-27	N/A
6/30/2023	1	-18	-38	-36	N/A
3/31/2023	1	-11	-43	-41	N/A
12/31/2022	1	-19	-50	-46	N/A
9/30/2022	-1	-22	-47	-43	N/A
6/30/2022	0	-34	-46	-43	N/A
3/31/2022	1	-43	-42	-39	N/A
12/31/2021	2	-44	-38	-36	N/A
9/30/2021	5	-35	-37	-35	N/A
6/30/2021	4	-28	-32	-30	N/A
3/31/2021	2	-26	-31	-29	N/A
12/31/2020	1	-30	-27	-26	N/A
9/30/2020	1	-32	-27	-25	N/A
6/30/2020	0	-30	-25	-24	N/A
3/31/2020	0	-26	-21	-20	N/A
12/31/2019	N/A	-22	-21	-20	N/A
9/30/2019	N/A	-19	-17	-17	N/A
6/30/2019	N/A	-17	-15	-14	N/A
3/31/2019	N/A	-16	-16	-16	N/A
12/31/2018	N/A	-16	-12	-12	N/A
9/30/2018	N/A	-15	-13	-13	N/A
6/30/2018	N/A	-19	-14	-14	N/A
3/31/2018	N/A	-18	-13	-13	N/A
12/31/2017	N/A	-19	N/A	-13	N/A
9/30/2017	N/A	-19	N/A	-13	N/A
6/30/2017	N/A	-14	N/A	-10	N/A
3/31/2017	N/A	-13	N/A	-9	N/A
12/31/2016	N/A	-11	N/A	-8	N/A
9/30/2016	N/A	-12	N/A	-7	N/A
6/30/2016	N/A	-11	N/A	-7	N/A
3/31/2016	N/A	-10	N/A	-6	N/A
12/31/2015	N/A	-9	N/A	-4	N/A
9/30/2015	N/A	-7	N/A	-3	N/A
6/30/2015	N/A	-5	N/A	-2	N/A
3/31/2015	N/A	-5	N/A	-1	N/A
12/31/2014	N/A	-5	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: OCX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: OCX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: OCX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: OCXの収益 ( 64% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: OCXの収益 ( 64% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: OCXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

OncoCyte 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus forecasts updated

Price target decreased to US$2.13

Consensus forecasts updated

Price target decreased to US$3.61

Price target decreased to US$5.02

Consensus revenue estimates fall by 28%

Recent updates

OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer

Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial

Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results

OncoCyte Corporation to Report Q1, 2024 Results on May 15, 2024

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

OncoCyte Corporation announced that it has received $15.8 million in funding

Broadwood Capital, Inc. Engages with OncoCyte Corporation

OncoCyte Corporation announced that it expects to receive $15.8 million in funding

OncoCyte Corporation announced delayed annual 10-K filing

Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays

OncoCyte Corporation to Report Q3, 2023 Results on Nov 09, 2023

Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage

Oncocyte Corporation Announces Executive Changes

OncoCyte Regains Compliance with Nasdaq Listing Requirements

OncoCyte Corporation to Report Q2, 2023 Results on Aug 10, 2023

Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients

Oncocyte Announces 1-For-20 Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Oncocyte Applies to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

OncoCyte Corporation Announces Reduction of Workforce

OncoCyte Corporation Announces Executive Changes

Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023

Consensus forecasts updated

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$2.13

OncoCyte Corporation to Report Q3, 2022 Results on Nov 10, 2022

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oncocyte Corporation Appoints James Liu as Controller and Principal Accounting Officer

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on Determarx to CMS

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

Independent Chairman recently bought US$144k worth of stock

OncoCyte Corporation Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

OncoCyte Corporation Appoints Anish John as Chief Financial Officer

OncoCyte Corporation Announces the Appointment of John Peter Gutfreund as Independent Member of its Board of Directors

OncoCyte Corporation to Report Q2, 2022 Results on Aug 10, 2022

OncoCyte Corporation Announces Resignation of Li Yu as Controller and Principal Accounting Officer

OncoCyte Corporation(NasdaqGM:OCX) dropped from Russell 2000 Dynamic Index

OncoCyte Corporation, Annual General Meeting, Jul 15, 2022

Consensus forecasts updated

Price target decreased to US$3.61

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oncocyte Corporation Completes Validation of TheraSure™ Transplant Monitor Test

Revisiting OncoCyte Corp.

High number of new directors

Price target decreased to US$5.02

Broadwood Capital Engages in Discussions with OncoCyte Corporation

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.000001 million.

Consensus revenue estimates fall by 28%

Full year 2021 earnings: EPS exceeds analyst expectations

OncoCyte Corporation to Report Q4, 2021 Results on Mar 10, 2022

Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?

OncoCyte Corporation Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer

Price target decreased to US$7.80

Price target decreased to US$8.00

Oncocyte Corporation Announces Results from DetermaIO™ Test

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2020)

Broadwood Partners Engages in Discussions with OncoCyte Corporation

Oncocyte Corporation Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting

Consensus forecasts updated

Oncocyte Corporation Launches Nationwide, Prospective, Real-World Registry for Patients with Potentially Curable Early-Stage Lung Cancer

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 2Q 2020)

OncoCyte signs an at-the-market agreement to sell $50M of common stock

Despite Lacking Profits OncoCyte (NASDAQ:OCX) Seems To Be On Top Of Its Debt